• Researcher Profile

    Thanh U. Barbie, MD

     
    Thanh U. Barbie, MD
     
    Instructor in Surgery, Harvard Medical School

    Center/Program

    Breast Oncology

    Office phone: 617-983-7777
    Fax: 617-983-7779

    Preferred contact method: appointment phone

    View Physician Profile
     
     

    Interests

    Breast cancer surgery, Novel therapies for breast cancer


    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02215

    Select Publications

    • Masiakos PT, MacLaughlin DT, Maheswaran S, Teixiera J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha(Barbie) TU, Preffer FI, Donahoe PK. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian Inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res. 1999 Nov; 5(11): 3488-99.
    • Segev DL, Ha(Barbie) TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughin DT, Donahoe PK, Maheswaran S. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFKappa B-mediated pathway. J Biol Chem. 2000 Sep 15; 275(37): 28371-9.
    • Ha(Barbie) TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK, Maheswaran S. Mullerian inhibiting substance inhibits ovarian cell growth through an Rbindependent mechanism. J Biol Chem. 2000 Nov 24;275(47):37101-9.
    • Hoshiya Y, Gupta V, Segev DL, Hoshiya M, Carey JL, Sasur LM, Tran TT, Ha(Barbie) TU, Maheswaran S. Mullerian Inhibiting Substance induces NFkBsignaling in breast and prostate cancer cells. Mol Cell Endocrinol. 2003; Dec15; 211 (1-2): 43-9.
    • Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A. 2003;100(26):15601-6.
    • Soysal SD, Muenst S, Barbie TU, Fleming T, Gao F, Spizzo G, Oertli D, Viehl CT, Obermann EC, Gillanders WE. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+, basal-like, and
      HER2 intrinsic subtypes of breast cancer. Br J Cancer. 2013 Mar 21. doi: 10.1038/bjc.2013.80.
    • Zhu Z, Aref A, Cohoon T, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W, Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ, Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA. Inhibition of KRAS-Driven Tumorigenicity by interruption of an Autocrine Cytokine Circuit. Cancer Discovery. 2014 Apr;
      4(4): 452-65. doi: 10.1158/2159-8290. CD-13-0646.
View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now